[Phosphodiesterase-4 inhibitors: a new target in treatment of COPD]

Dtsch Med Wochenschr. 2011 Nov;136(44):2267-70. doi: 10.1055/s-0031-1292040. Epub 2011 Oct 25.
[Article in German]

Abstract

Roflumilast is a new drug with innovative pharmacodynamic properties for use in patients with chronic obstructive pulmonary disease (COPD). By selective inhibition of phosphodiesterase-4 roflumilast targets inflammatory processes in COPD, with beneficial effects on smoking-induced bronchial inflammation, fibrotic remodeling, mucociliary malfunction and oxidative stress.

Publication types

  • Review

MeSH terms

  • Aminopyridines / adverse effects
  • Aminopyridines / pharmacokinetics
  • Aminopyridines / therapeutic use*
  • Benzamides / adverse effects
  • Benzamides / pharmacokinetics
  • Benzamides / therapeutic use*
  • Bronchodilator Agents / adverse effects
  • Bronchodilator Agents / pharmacokinetics
  • Bronchodilator Agents / therapeutic use
  • Contraindications
  • Cyclopropanes / adverse effects
  • Cyclopropanes / pharmacokinetics
  • Cyclopropanes / therapeutic use
  • Double-Blind Method
  • Drug Interactions
  • Drug Therapy, Combination
  • Forced Expiratory Volume / drug effects
  • Humans
  • Mucociliary Clearance / drug effects
  • Oxidative Stress / drug effects
  • Phosphodiesterase 4 Inhibitors / adverse effects
  • Phosphodiesterase 4 Inhibitors / pharmacokinetics
  • Phosphodiesterase 4 Inhibitors / therapeutic use*
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Randomized Controlled Trials as Topic
  • Smoking / adverse effects

Substances

  • Aminopyridines
  • Benzamides
  • Bronchodilator Agents
  • Cyclopropanes
  • Phosphodiesterase 4 Inhibitors
  • Roflumilast